Testicular cancer is the most common cancer in young men aged 15–35 and is highly curable even at advanced stages, with overall survival rates exceeding 95% for all stages combined. It is divided into seminoma and non-seminomatous germ cell tumors, and cisplatin-based combination chemotherapy transformed outcomes starting in the 1970s.
What's actually going on in research
Because most patients are cured with existing treatments, research increasingly focuses on reducing long-term toxicity from chemotherapy and radiation — including secondary cancers, cardiovascular disease, neuropathy, and infertility — while maintaining high cure rates. Trials are testing less intensive regimens for good-risk metastatic disease and new agents for the small proportion with refractory or platinum-resistant disease, where outcomes remain poor. Immunotherapy with checkpoint inhibitors has so far shown modest activity in germ cell tumors.
Treatment de-intensification
Trials are studying whether good-risk metastatic seminoma and non-seminomatous tumors can be cured with fewer cycles of BEP chemotherapy or substitution of carboplatin, reducing toxicity without sacrificing cure rates.
Platinum-resistant disease
For the minority with refractory germ cell tumors, trials are testing immune checkpoint inhibitors, antibody-drug conjugates, and novel cytotoxic combinations to find regimens that can achieve durable remissions.
Fertility and late effects
Sperm cryopreservation, fertility-sparing surgical approaches, and counseling trials are studying how to preserve fertility and minimize long-term health consequences of chemotherapy and radiation in young survivors.
What to know before you search
Eligibility depends on histology (seminoma versus non-seminomatous), stage, whether prior platinum-based chemotherapy was given, and current tumor marker levels.
What types of trials are currently open
- De-intensification trials — Testing fewer chemotherapy cycles or less toxic regimens in good-risk metastatic germ cell tumors.
- Refractory disease trials — Evaluating checkpoint inhibitors and novel agents for platinum-resistant or relapsed testicular cancer.
- Surveillance trials — Refining imaging-based surveillance to detect relapse early while reducing unnecessary imaging exposure.
- Fertility preservation trials — Studying sperm banking, hormonal interventions, and fertility outcomes after germ cell tumor treatment.
- Late effects trials — Monitoring and treating cardiovascular, neurological, and second cancer risks in long-term survivors.
Recently added Testicular Cancer trials
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity
This is a study exploring measurable markers in the blood of patients with testicular tumors. The investigators will focus on the importance of measuring and analyzing these markers for their prognostic value and predictive response to treatment.
Find Testicular Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.